30
Participants
Start Date
December 31, 2008
Primary Completion Date
August 31, 2010
Study Completion Date
October 31, 2010
Fluphenazine HCl
Fluphenazine HCl will be administered intravenously. To quickly reach and maintain the target bone marrow concentration for 18 hours, the study drug will be administered using 3 bolus injections (0, 6, and 12 hours). Fluphenazine will be dose-escalated according to a modified Fibonacci scheme, terminating in 40% increments. Treatments will be administered on days 1 and 8 of every 21 day cycle.
NOT_YET_RECRUITING
University of Pittsburgh Cancer Institute Hillman Cancer Center, Pittsburgh
RECRUITING
Hospital of the University of Pennsylvania, Philadelphia
RECRUITING
Cancer Therapy and Research Center at the UT Health Sciences Center at San Antonio, San Antonio
Lead Sponsor
Immune Control
INDUSTRY